Cheri Adams, MSHS, RN, RAC
Assistant Director, Regulatory Affairs & Pharmacovigilance
As Assistant Director of Regulatory Affairs and Pharmacovigilance at the Gates Institute, Cheri leads the regulatory affairs and product safety programs for investigational cell and gene therapy products. She oversees regulatory strategy, operations, and pharmacovigilance, helping shepherd early-phase investigational products from scientific concept to clinical evaluation through risk-based regulatory strategy and rigorous safety oversight.
Cheri joined the Gates Institute in January 2023 after serving as a founding member of the Cell Therapy Operations Program within the Office of the Vice Chancellor for Research. In that role, she helped lay the operational and regulatory foundation for CU Anschutz’s growth as a leading cell and gene therapy hub, building core processes to support the development, oversight, and translation of cellular therapy programs across the campus. Before that, she spent 11 years at Children’s Hospital Colorado as a Phase I oncology research nurse and regulatory affairs lead.
Cheri earned a B.S. in Nursing and Microbiology from the University of Arizona and an M.S. in Regulatory Affairs from the George Washington University School of Medicine and Health Sciences.